29 completed, 11 recruiting, 6 active not recruiting, 5 unknown. 22 Phase 2, 10 Phase 3, 7 Phase 1, 4 Not applicable, 3 Phase 4.
Follow Servier: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| S243249 Monotherapy in Patients With Relapsed or Refractory Acute Leukemia With a KMT2A or NUP98 Translocation or Relapsed or Refractory AML With NPM1c Mutation S243249 600mg, S243249 400mg, S243249 450mg - Relapsed or Refractory Acute Leukemia, Relapsed or Refractory Acute Myeloid Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 80 | 2026-10-20 | 2026-09-03 |
| A Study to Evaluate S241656 Alone or in Combination in Participants With Selected Myeloid Malignancies S241656, Posaconazole - Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia | Phase 1 / Phase 2 | Not yet recruiting | Servier | 64 | 2026-09-15 | 2026-07-22 |
| Ivosidenib as Post-HSCT Maintenance for AML Ivosidenib, Placebo - IDH1 Mutation, Acute Myeloid Leukemia (AML) | Phase 2 | Recruiting | Massachusetts General Hospital | 75 | 2026-01-16 | 2026-10-05 |
| BETWEEN: Biweekly Bevacizumab + Trifluridine/Tipiracil to Reduce Grade 3-4 Neutropenia in mCRC Patients Trifluridine/tipiracil, Bevacizumab - Metastatic Colorectal Cancer | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 162 | 2025-09-01 | 2025-07-17 |
| ViCToRy: Vorasidenib in Combination With Tumor Specific Peptide Vaccine for Recurrent IDH1 Mutant Lower Grade Gliomas PEPIDH1M vaccine + vorasidenib - Low Grade Glioma of Brain | Phase 1 | Recruiting | Katy Peters, MD, PhD | 48 | 2025-07-15 | 2026-08-24 |
| PANORAMIX : Optimizing 1st-line NALIRIFOX and Exploring Microbiota's Role in 2nd Line Pancreatic Cancer Treatment Nal-IRI, Ciprofloxacin, Paclitaxel - PDAC - Pancreatic Ductal Adenocarcinoma | Phase 2 | Not yet recruiting | GERCOR - Multidisciplinary Oncology Cooperative Group | 206 | 2025-07-01 | 2025-07-01 |
| Safety of Trifluridine/Tipiracil in Patients With Dihydropyrimidine Dehydrogenase Deficiency Diagnosed With Metastatic Colorectal or Gastroesophageal Cancer Lonsurf, Oxaliplatin, Panitumumab - Metastatic Colorectal Cancer, Metastatic Gastroesophageal Adenocarcinoma | Phase 2 | Recruiting | UNICANCER | 73 | 2025-03-21 | 2025-12-10 |
| Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation Vorasidenib, Placebo - Residual or Recurrent Grade 2 IDH Mutant Glioma | Phase 3 | Active not recruiting | Servier | 57 | 2024-10-18 | 2026-06-04 |
| Personalized Medicine for Advanced Biliary Cancer Patients Futibatinib, Ivosidenib, Zanidatamab - Biliary Tract Neoplasms | Phase 3 | Recruiting | UNICANCER | 800 | 2024-07-18 | 2026-05-19 |
| RAPID AFib Decision Aid for Stroke Prevention in Atrial Fibrillation Electronic patient decision aid, Information - Atrial Fibrillation | Not applicable | Recruiting | University of Calgary | 60 | 2024-04-01 | 2025-04-02 |
| A Phase 2 Study of Ivosidenib in Previously Treated Japanese Subjects With Nonresectable or Metastatic Cholangiocarcinoma With an IDH1 Mutation Ivosidenib - Cholangiocarcinoma Non-resectable, Cholangiocarcinoma Metastatic | Phase 2 | Active not recruiting | Servier | 12 | 2023-10-10 | 2025-12-09 |
| Real World Efficacy, Safety of Nanoliposomal Irinotecan With Fluorouracil and Folinic Acid in Metastatic Pancreatic Cancer After Previous Gemcitabine-based Therapy Pancreatic Adenocarcinoma Metastatic | Completed | University Hospital, Bordeaux | 58 | 2023-10-06 | 2024-01-12 | |
| Adult Acute Lymphoblastic Leukemia Treated With Pediatric Regimen in Brazil Prednisone, Vincristin, Daunorubicin - Acute Lymphoid Leukemia, Minimal Residual Disease | Recruiting | Instituto do Cancer do Estado de São Paulo | 180 | 2023-09-05 | 2025-05-07 | |
| Rapid Management of Resistant Hypertension in the Public Health System (Fast Control) Triple Fixed-Dose Combination (Perindoprile/Indapamide/Amlodipine), Usual Care Antihypertensive Regimen - Apparent Resistant Hypertension, Hypertension | Not applicable | Recruiting | Instituto Dante Pazzanese de Cardiologia | 142 | 2023-07-15 | 2025-12-02 |
| Oxaliplatin ± Nivolumab in Combination With Trifluridine/Tipiracil or 5-fluorouracile in Frail Patients With Advanced, Recurrent or Metastatic Gastric, Oesophageal or Gastroesophageal Junction Cancer Trifluridine/Tipiracil, Oxaliplatin, FOLFOX regimen - Gastric Adenocarcinoma, Esophagus Adenocarcinoma | Phase 2 | Active not recruiting | UNICANCER | 118 | 2023-06-23 | 2026-07-24 |
| Exploiting Circulating Tumour DNA to Intensify the Postoperative Treatment Resected Colon Cancer Patients 5-Fluorouracil continuous infusion FOLFOXIRI schedule, 5-Fluorouracil bolus FOLFOX schedule, 5-Fluorouracil continuous infusion FOLFOX schedule - Stage II Colon Cancer, Stage III Colon Cancer | Phase 2 | Suspended | Gruppo Oncologico del Nord-Ovest | 477 | 2023-05-17 | 2026-02-03 |
| Kuwait Heart Foundation Registry of Acute Coronary Events Observational registry with no intervention. - ACS | Completed | Gulf Heart Association | 10812 | 2023-05-15 | 2025-08-20 | |
| CalPeg for Newly Diagnosed Acute Lymphoblastic Leukemia (ALL) Hyper CVAD Protocol (Standard of Care Multi-Agent Chemotherapy), Calaspargase Pegol, Rituximab - Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | H. Lee Moffitt Cancer Center and Research Institute | 7 | 2023-05-01 | 2026-03-06 |
| Venetoclax Basket Trial for High Risk Hematologic Malignancies Venetoclax, Azacitidine, Cytarabine - Myelodysplastic Syndromes, de Novo, Myelodysplastic Syndromes, Secondary | Phase 1 | Recruiting | Andrew E. Place, MD | 30 | 2023-03-29 | 2026-03-12 |
| Non-drug Treatment Study in Parkinson's Disease Patients and Healthy Volunteers to Collect Biological Samples in Order to Assess ex Vivo the Activity of Candidate Therapies and Develop Novel Analytical Methods for Biomarkers Blood sample collection and an optional cerebrospinal fluid (CSF) collection, Blood sample collection - Parkinson Disease | Early Phase 1 | Completed | Servier | 45 | 2022-07-11 | 2025-04-11 |
Showing 20 of 59. Sign in to see all of them.
Precursor Cell Lymphoblastic Leukemia-Lymphoma (6) · Heart Failure (5) · Colorectal Neoplasms (4) · Essential Hypertension (4) · Leukemia, Myeloid, Acute (4) · Recurrence (4) · Atrial Fibrillation (3) · Neoplasm Metastasis (3) · Neoplasms (3) · Biliary Tract Neoplasms (2) · Cardiotoxicity (2) · Cholangiocarcinoma (2) · Glioma (2) · Hypertension (2) · Leukemia (2)
Leucovorin (9) · Fluorouracil (7) · trifluridine tipiracil drug combination (7) · Oxaliplatin (6) · irinotecan sucrosofate (6) · Cytarabine (4) · Doxorubicin (4) · Methotrexate (4) · Perindopril (4) · Vincristine (4) · Amlodipine (3) · Cyclophosphamide (3) · Dexamethasone (3) · Gemcitabine (3) · Mercaptopurine (3)
France (15) · Germany (10) · Canada (9) · United States (8) · Netherlands (4) · United Kingdom (4) · Belgium (3) · Brazil (3) · Italy (3) · Australia (2) · China (2) · Estonia (2) · Ireland (2) · Lithuania (2) · Poland (2)
A. Elise van Leeuwen-Stok, PhD (1) · Alain Cohen-Solal, PHD (1) · Alexandra Konradi (1) · Amir T Fathi, MD (1) · Andrew E Place, MD, PhD (1) · Arndt Vogel, Prof. (1) · Bijal Shah, MD (1) · Christoph Roderburg, Prof. (1) · Dirk Waldschmidt (1) · Eduardo M Rego, MD PhD (1)
PMID 12493255, PMID 21638157, PMID 22394464, PMID 23504379, PMID 24780062, PMID 25157115, PMID 25234206, PMID 25908674, PMID 26523214, PMID 27006512, PMID 27590190, PMID 28516737, PMID 28694343, PMID 28820057, PMID 29445831, PMID 31302707, PMID 31646981, PMID 31779564, PMID 32029495, PMID 32248819, PMID 33141449, PMID 34933343, PMID 35501736, PMID 35687781, PMID 36109108, PMID 37217885, PMID 37260368, PMID 37287870, PMID 37590267, PMID 38762353, PMID 38843469, PMID 38870977, PMID 39316768, PMID 40017682, PMID 40147791, PMID 40299195, PMID 40876084, PMID 40905823, PMID 41316032, PMID 41469545, PMID 42154791
2016 (2), 2025 (2), 2014 (1), 2018 (1), 2019 (1)